A Dihydroflavonoid Naringin Extends the Lifespan of C. elegans and Delays the Progression of Aging-Related Diseases in PD/AD Models via DAF-16

Figure 3

Naringin declines the progression of aging-related diseases. (a) Representative images of the α-synuclein in NL5901 treated with or without naringin. The aggregation of α-synuclein in NL5901 treated with or without naringin was captured with a Leica epifluorescence microscope and analyzed by using the image processing software ImageJ. 50 animals of each strain were scored in two independent trials. (b) Aging-related movements of NL5901 with nontreated control plates and 50 μM naringin. The mean body movement speed is found in Table S2 (Supplementary information). (c) Representative images of the head neurons of BZ555 using different ways of rescue after 6-OHDA induction. After the rescue of 50 μM naringin, the head neurons showed slow degenerative changes, and the degree of protection was basically consistent with levodopa which is the anti-Parkinson’s disease drug. 40 animals of each strain were scored in each independent trial. Statistical details and repeats of these experiments are summarized in Table S6 (Supplementary information). (d) The paralysis phenotype associated with muscle Aβ expression is suppression by 50 μM naringin treatment from the L3 stage larvae in the transgenic strain CL4176. Shown is the independent experiment with 70-100 animals in indicated time points after temperature upshift to 25°C. Statistical details and repeats of these experiments are summarized in Table S8 (Supplementary information).

(a)

(b)

(c)

(d)